Biodexa Pharmaceuticals Plc
BDRX
$7.51
-$0.26-3.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -90.71% | -83.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -90.71% | -83.71% |
| Cost of Revenue | 25.91% | 30.51% | 37.77% | 9.08% | -15.16% |
| Gross Profit | -28.57% | -38.44% | -51.96% | -20.28% | 6.91% |
| SG&A Expenses | 52.97% | 38.28% | 29.01% | -26.38% | -41.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -326.70% | -224.43% | -127.84% | -133.06% | -151.43% |
| Total Operating Expenses | 36.40% | 33.38% | 33.85% | -9.07% | -28.50% |
| Operating Income | -38.08% | -37.98% | -41.44% | 4.79% | 25.38% |
| Income Before Tax | 5.10% | 13.00% | 18.02% | 17.81% | 17.19% |
| Income Tax Expenses | -22.64% | 15.58% | 36.51% | 56.60% | 67.34% |
| Earnings from Continuing Operations | 6.09% | 12.88% | 16.97% | 14.81% | 12.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.09% | 12.88% | 16.97% | 14.81% | 12.40% |
| EBIT | -38.08% | -37.98% | -41.44% | 4.79% | 25.38% |
| EBITDA | -39.11% | -39.11% | -42.70% | 4.71% | 25.72% |
| EPS Basic | 47.68% | -88.12% | -- | -- | -- |
| Normalized Basic EPS | 47.10% | -89.18% | -- | -- | -- |
| EPS Diluted | 47.68% | -88.12% | -- | -- | -- |
| Normalized Diluted EPS | 47.10% | -89.18% | -- | -- | -- |
| Average Basic Shares Outstanding | 872.26% | 1,174.09% | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |